Edaravone (English Wikipedia)

Bailly C, Hecquet PE, Kouach M, Thuru X, Goossens JF (May 2020). "Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone". Bioorganic & Medicinal Chemistry. 28 (10) 115463. doi:10.1016/j.bmc.2020.115463. PMID 32241621. S2CID 214766793.
Petrov D, Mansfield C, Moussy A, Hermine O (2017). "ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?". Frontiers in Aging Neuroscience. 9: 68. doi:10.3389/fnagi.2017.00068. PMC 5360725. PMID 28382000.
Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, et al. (2015). "Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry". Neurologia Medico-chirurgica. 55 (3). Tokyo: 241–247. doi:10.2176/nmc.ra.2014-0219. PMC 4533339. PMID 25739433.
Enomoto M, Endo A, Yatsushige H, Fushimi K, Otomo Y (March 2019). "Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy". Stroke. 50 (3): 652–658. doi:10.1161/STROKEAHA.118.023815. PMID 30741623.
Rong WT, Lu YP, Tao Q, Guo M, Lu Y, Ren Y, et al. (February 2014). "Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes". Journal of Pharmaceutical Sciences. 103 (2): 730–742. Bibcode:2014JPhmS.103..730R. doi:10.1002/jps.23807. PMID 24311389.
Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, et al. (March 2021). "Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial". Stroke. 52 (3): 772–780. doi:10.1161/STROKEAHA.120.031197. PMID 33588596.
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, et al. (1 April 2024). "Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial". JAMA Neurology. 81 (4): 319–326. doi:10.1001/jamaneurol.2023.5716. PMC 10877503. PMID 38372981.

evaluategroup.com (Global: low place; English: low place)

"Launching of Radicut Injection. 30 mg" (Press release). Mitsubishi-Tokyo Pharmaceuticals via Evaluate. 23 May 2001. Archived from the original on 3 July 2022. Retrieved 9 May 2017.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"FDA Approves Oral Form of ALS Treatment". U.S. Food and Drug Administration (FDA). 12 May 2022. Archived from the original on 12 May 2022. Retrieved 12 May 2022. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 23 October 2020. Retrieved 16 September 2020.
"FDA approves drug to treat ALS". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 8 May 2017. Retrieved 7 May 2017.

accessdata.fda.gov

"NDA 209176 Approval letter" (PDF). U.S. Food and Drug Administration (FDA). 5 May 2017. Archived from the original (PDF) on 10 May 2018. Retrieved 13 May 2017.
"Radicava (edaravone) Injection". U.S. Food and Drug Administration (FDA). 20 June 2017. Archived from the original on 13 May 2022. Retrieved 12 May 2022.
NDA Approval^{[dead link]} fda.gov "NDA APPROVAL" (PDF). Archived from the original on 13 May 2022. Retrieved 13 May 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link)

ferrer.com (Global: low place; English: low place)

"Ferrer reports top-line results from Phase III ADORE study in ALS | Ferrer". www.ferrer.com. Archived from the original on 8 March 2024. Retrieved 8 March 2024.

fiercepharma.com (Global: low place; English: 8,921^st place)

Lane EJ (20 April 2016). "Mitsubishi Tanabe says ALS drug meets PhIII endpoint". FiercePharma. Archived from the original on 13 February 2019. Retrieved 13 May 2017.

forbes.com (Global: 54^th place; English: 48^th place)

Herper M. "The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan". Forbes. Archived from the original on 6 May 2017. Retrieved 10 May 2017.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Rong WT, Lu YP, Tao Q, Guo M, Lu Y, Ren Y, et al. (February 2014). "Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes". Journal of Pharmaceutical Sciences. 103 (2): 730–742. Bibcode:2014JPhmS.103..730R. doi:10.1002/jps.23807. PMID 24311389.

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

"Regulatory Decision Summary for Radicava". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

icer.org (Global: low place; English: low place)

Makam AN, Suh K, Nikitin D, Carlson J, Richardson M, Mohammed R, et al. (4 August 2022). "AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis: Evidence Report" (PDF). Institute for Clinical and Economic Review: D6.

mt-pharma-america.com (Global: low place; English: low place)

Media_MTPA@mt-pharma-us.com (1 August 2023). "Press Releases". Mitsubishi Tanabe Pharma America. Archived from the original on 8 March 2024. Retrieved 8 March 2024.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Bailly C, Hecquet PE, Kouach M, Thuru X, Goossens JF (May 2020). "Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone". Bioorganic & Medicinal Chemistry. 28 (10) 115463. doi:10.1016/j.bmc.2020.115463. PMID 32241621. S2CID 214766793.
Petrov D, Mansfield C, Moussy A, Hermine O (2017). "ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?". Frontiers in Aging Neuroscience. 9: 68. doi:10.3389/fnagi.2017.00068. PMC 5360725. PMID 28382000.
Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, et al. (2015). "Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry". Neurologia Medico-chirurgica. 55 (3). Tokyo: 241–247. doi:10.2176/nmc.ra.2014-0219. PMC 4533339. PMID 25739433.
Enomoto M, Endo A, Yatsushige H, Fushimi K, Otomo Y (March 2019). "Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy". Stroke. 50 (3): 652–658. doi:10.1161/STROKEAHA.118.023815. PMID 30741623.
Rong WT, Lu YP, Tao Q, Guo M, Lu Y, Ren Y, et al. (February 2014). "Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes". Journal of Pharmaceutical Sciences. 103 (2): 730–742. Bibcode:2014JPhmS.103..730R. doi:10.1002/jps.23807. PMID 24311389.
Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, et al. (March 2021). "Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial". Stroke. 52 (3): 772–780. doi:10.1161/STROKEAHA.120.031197. PMID 33588596.
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, et al. (1 April 2024). "Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial". JAMA Neurology. 81 (4): 319–326. doi:10.1001/jamaneurol.2023.5716. PMC 10877503. PMID 38372981.

ncbi.nlm.nih.gov

Petrov D, Mansfield C, Moussy A, Hermine O (2017). "ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?". Frontiers in Aging Neuroscience. 9: 68. doi:10.3389/fnagi.2017.00068. PMC 5360725. PMID 28382000.
Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, et al. (2015). "Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry". Neurologia Medico-chirurgica. 55 (3). Tokyo: 241–247. doi:10.2176/nmc.ra.2014-0219. PMC 4533339. PMID 25739433.
Fu Y, Wang A, Tang R, Li S, Tian X, Xia X, et al. (1 April 2024). "Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial". JAMA Neurology. 81 (4): 319–326. doi:10.1001/jamaneurol.2023.5716. PMC 10877503. PMID 38372981.

dailymed.nlm.nih.gov

"Radicava- edaravone injection Radicava ORS- edaravone kit". DailyMed. 12 May 2022. Archived from the original on 27 January 2022. Retrieved 27 May 2022.

nytimes.com (Global: 7^th place; English: 7^th place)

Grady D (5 May 2017). "A Second Drug Is Approved to Treat A.L.S." The New York Times. Archived from the original on 4 April 2018. Retrieved 8 May 2017.

okayama-u.ac.jp (Global: low place; English: low place)

"History of Okayama University Hospital". OKAYAMA UNIV. HOSPITAL (in Japanese).

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Bailly C, Hecquet PE, Kouach M, Thuru X, Goossens JF (May 2020). "Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone". Bioorganic & Medicinal Chemistry. 28 (10) 115463. doi:10.1016/j.bmc.2020.115463. PMID 32241621. S2CID 214766793.

springer.com (Global: 274^th place; English: 309^th place)

adisinsight.springer.com

"Edaravone oral". AdisInsight. Archived from the original on 7 July 2017. Retrieved 13 May 2017.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Radicava". Therapeutic Goods Administration (TGA). 24 February 2023. Archived from the original on 24 February 2023. Retrieved 7 April 2023.
"Radicava edaravone 30 mg/20 mL concentrated injection ampoule (375455)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.

web.archive.org (Global: 1^st place; English: 1^st place)

"Radicava". Therapeutic Goods Administration (TGA). 24 February 2023. Archived from the original on 24 February 2023. Retrieved 7 April 2023.
"Radicava edaravone 30 mg/20 mL concentrated injection ampoule (375455)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
"Regulatory Decision Summary for Radicava". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
"Radicava- edaravone injection Radicava ORS- edaravone kit". DailyMed. 12 May 2022. Archived from the original on 27 January 2022. Retrieved 27 May 2022.
"FDA Approves Oral Form of ALS Treatment". U.S. Food and Drug Administration (FDA). 12 May 2022. Archived from the original on 12 May 2022. Retrieved 12 May 2022. This article incorporates text from this source, which is in the public domain.
New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 23 October 2020. Retrieved 16 September 2020.
"FDA Approves Edaravone as a Treatment for ALS". Research ALS. Archived from the original on 12 February 2019. Retrieved 10 May 2017.
Herper M. "The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan". Forbes. Archived from the original on 6 May 2017. Retrieved 10 May 2017.
Lane EJ (20 April 2016). "Mitsubishi Tanabe says ALS drug meets PhIII endpoint". FiercePharma. Archived from the original on 13 February 2019. Retrieved 13 May 2017.
"FDA approves drug to treat ALS". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 8 May 2017. Retrieved 7 May 2017.
"NDA 209176 Approval letter" (PDF). U.S. Food and Drug Administration (FDA). 5 May 2017. Archived from the original (PDF) on 10 May 2018. Retrieved 13 May 2017.
"Radicava (edaravone) Injection". U.S. Food and Drug Administration (FDA). 20 June 2017. Archived from the original on 13 May 2022. Retrieved 12 May 2022.
"Edaravone oral". AdisInsight. Archived from the original on 7 July 2017. Retrieved 13 May 2017.
"Ferrer reports top-line results from Phase III ADORE study in ALS | Ferrer". www.ferrer.com. Archived from the original on 8 March 2024. Retrieved 8 March 2024.
NDA Approval^{[dead link]} fda.gov "NDA APPROVAL" (PDF). Archived from the original on 13 May 2022. Retrieved 13 May 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
Media_MTPA@mt-pharma-us.com (1 August 2023). "Press Releases". Mitsubishi Tanabe Pharma America. Archived from the original on 8 March 2024. Retrieved 8 March 2024.
"Launching of Radicut Injection. 30 mg" (Press release). Mitsubishi-Tokyo Pharmaceuticals via Evaluate. 23 May 2001. Archived from the original on 3 July 2022. Retrieved 9 May 2017.
Grady D (5 May 2017). "A Second Drug Is Approved to Treat A.L.S." The New York Times. Archived from the original on 4 April 2018. Retrieved 8 May 2017.

Edaravone (English Wikipedia)

alsresearchforum.org (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

evaluategroup.com (Global: low place; English: low place)

fda.gov (Global: 447th place; English: 338th place)

fda.gov

accessdata.fda.gov

ferrer.com (Global: low place; English: low place)

fiercepharma.com (Global: low place; English: 8,921st place)

forbes.com (Global: 54th place; English: 48th place)

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

icer.org (Global: low place; English: low place)

mt-pharma-america.com (Global: low place; English: low place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nytimes.com (Global: 7th place; English: 7th place)

okayama-u.ac.jp (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

springer.com (Global: 274th place; English: 309th place)

adisinsight.springer.com

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

web.archive.org (Global: 1st place; English: 1st place)

doi.org (Global: 2^nd place; English: 2^nd place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

forbes.com (Global: 54^th place; English: 48^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

nih.gov (Global: 4^th place; English: 4^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

springer.com (Global: 274^th place; English: 309^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)